ATE464060T1 - Peroral-verabreichte peptide zur besserung von atherosklerose - Google Patents
Peroral-verabreichte peptide zur besserung von atheroskleroseInfo
- Publication number
- ATE464060T1 ATE464060T1 AT01966198T AT01966198T ATE464060T1 AT E464060 T1 ATE464060 T1 AT E464060T1 AT 01966198 T AT01966198 T AT 01966198T AT 01966198 T AT01966198 T AT 01966198T AT E464060 T1 ATE464060 T1 AT E464060T1
- Authority
- AT
- Austria
- Prior art keywords
- atherosclerosis
- improvement
- peptides
- administered perorally
- peptides administered
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/775—Apolipopeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/08—Antibacterial agents for leprosy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Heart & Thoracic Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Cardiology (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Toxicology (AREA)
- Neurology (AREA)
- Biochemistry (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Dermatology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Vascular Medicine (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/645,454 US6664230B1 (en) | 2000-08-24 | 2000-08-24 | Orally administered peptides to ameliorate atherosclerosis |
PCT/US2001/026497 WO2002015923A1 (en) | 2000-08-24 | 2001-08-23 | Orally administered peptides to ameliorate atherosclerosis |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE464060T1 true ATE464060T1 (de) | 2010-04-15 |
Family
ID=24589089
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT01966198T ATE464060T1 (de) | 2000-08-24 | 2001-08-23 | Peroral-verabreichte peptide zur besserung von atherosklerose |
AT07007775T ATE506958T1 (de) | 2000-08-24 | 2001-08-23 | Oral verabreichte peptide zur linderung von atherosklerose |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT07007775T ATE506958T1 (de) | 2000-08-24 | 2001-08-23 | Oral verabreichte peptide zur linderung von atherosklerose |
Country Status (16)
Country | Link |
---|---|
US (2) | US6664230B1 (de) |
EP (3) | EP1864675B1 (de) |
JP (6) | JP3822167B2 (de) |
CN (6) | CN100579984C (de) |
AT (2) | ATE464060T1 (de) |
AU (4) | AU8673201A (de) |
CA (3) | CA2639651C (de) |
CY (1) | CY1110204T1 (de) |
DE (2) | DE60141842D1 (de) |
DK (1) | DK1318828T3 (de) |
EA (2) | EA009528B1 (de) |
ES (2) | ES2342258T3 (de) |
HK (2) | HK1110011A1 (de) |
IL (3) | IL154545A0 (de) |
PT (1) | PT1318828E (de) |
WO (1) | WO2002015923A1 (de) |
Families Citing this family (86)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7144862B2 (en) * | 2000-08-24 | 2006-12-05 | The Regents Of The University Of California | Orally administered peptides to ameliorate atherosclerosis |
US7199102B2 (en) * | 2000-08-24 | 2007-04-03 | The Regents Of The University Of California | Orally administered peptides synergize statin activity |
US8568766B2 (en) | 2000-08-24 | 2013-10-29 | Gattadahalli M. Anantharamaiah | Peptides and peptide mimetics to treat pathologies associated with eye disease |
US7148197B2 (en) * | 2000-08-24 | 2006-12-12 | The Regents Of The University Of California | Orally administered small peptides synergize statin activity |
US7166578B2 (en) * | 2000-08-24 | 2007-01-23 | The Regents Of The University Of California | Orally administered peptides synergize statin activity |
US6664230B1 (en) * | 2000-08-24 | 2003-12-16 | The Regents Of The University Of California | Orally administered peptides to ameliorate atherosclerosis |
US7723303B2 (en) | 2000-08-24 | 2010-05-25 | The Regents Of The University Of California | Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response |
US6930085B2 (en) | 2002-04-05 | 2005-08-16 | The Regents Of The University Of California | G-type peptides to ameliorate atherosclerosis |
DE10222234A1 (de) * | 2002-05-16 | 2003-11-27 | Roche Diagnostics Gmbh | Kontroll- und Kalibrationsmaterial für Blutgerinnungstests |
WO2004041179A2 (en) * | 2002-10-30 | 2004-05-21 | The United States Of America As Represented By The Secretary Of Health And Human Services, Nih | Scavenger receptor b1 (cla-1) targeting for the treatment of infection, sepsis and inflammation |
AU2003290825C1 (en) * | 2002-11-13 | 2009-12-10 | The Uab Research Foundation | Synthetic single domain polypeptides mimicking apolipoprotein E and methods of use |
WO2004094471A2 (en) * | 2003-04-22 | 2004-11-04 | Avanir Pharmaceuticals | Mediators of reverse cholesterol transport for the treatment of hypercholesterolemia |
US20050159362A1 (en) * | 2003-04-22 | 2005-07-21 | Sircar Jagadish C. | Mediators of reverse cholesterol transport for the treatment of hypercholesterolemia |
GB0311081D0 (en) * | 2003-05-14 | 2003-06-18 | Btg Internat Limted | Treatment of neurodegenerative conditions |
EP1660071A1 (de) * | 2003-08-18 | 2006-05-31 | Btg International Limited | Behandlung von neurodegenerativen erkrankungen |
EP2306192B1 (de) | 2003-12-05 | 2015-10-14 | The Cleveland Clinic Foundation | Risikomarker für eine Herzkreislaufkrankheit |
GB0329958D0 (en) | 2003-12-24 | 2004-01-28 | Univ Manchester | Treatment of viral infections |
GB0404374D0 (en) | 2004-02-27 | 2004-03-31 | Univ Manchester | Treatment of bacterial infections |
AU2005233361B2 (en) * | 2004-04-15 | 2011-02-24 | Athera Biotechnologies Ab | Phosphorylcholine conjugates and corresponding antibodies |
ATE493973T1 (de) * | 2004-06-04 | 2011-01-15 | Teva Pharma | Irbesartan enthaltende pharmazeutische zusammensetzung |
TW200603795A (en) * | 2004-06-09 | 2006-02-01 | Avanir Pharmaceuticals | Mediators of reverse cholesterol transport for the treatment of hypercholesterolemia |
KR20070043711A (ko) * | 2004-06-09 | 2007-04-25 | 아바니르 파마슈티컬스 | 고콜레스테롤혈증과 관련 질환의 치료를 위한 소분자 |
CA2568394A1 (en) * | 2004-06-09 | 2005-12-29 | Avanir Pharmaceuticals | Heterocyclic derivatives for treatment of hyperlipidemia and related diseases |
BRPI0513402A (pt) * | 2004-07-16 | 2008-05-06 | Tufts College | miméticos de apolipoproteìna a1 e usos dos mesmos |
WO2006020498A2 (en) | 2004-08-11 | 2006-02-23 | The Cleveland Clinic Foundation | Therapeutic agents and methods for cardiovascular disease |
CA2577026A1 (en) * | 2004-08-11 | 2006-02-23 | The Regents Of The University Of California | Orally administered small peptides synergize statin activity |
CA2580501A1 (en) * | 2004-09-16 | 2006-03-30 | The Regents Of The University Of California | G-type peptides and other agents to ameliorate atherosclerosis and other pathologies |
WO2006053754A1 (en) * | 2004-11-19 | 2006-05-26 | Novartis Ag | COMBINATIONS OF ANTI-ATHEROSCLEROTIC PEPTIDES AND AN mTOR INHIBITING AGENT AND THEIR METHODS OF USE |
GB0425932D0 (en) * | 2004-11-25 | 2004-12-29 | Btg Int Ltd | Structured phospholipids |
EP1827472A4 (de) * | 2004-12-06 | 2012-09-05 | Univ California | Verfahren zur verbesserung der struktur und funktion von arteriolen |
GB0504333D0 (en) * | 2005-03-02 | 2005-04-06 | Btg Int Ltd | Treatment of cytokine dysregulation |
GB0504362D0 (en) * | 2005-03-02 | 2005-04-06 | Btg Int Ltd | Cytokine modulators |
US8206750B2 (en) | 2005-03-24 | 2012-06-26 | Cerenis Therapeutics Holding S.A. | Charged lipoprotein complexes and their uses |
US20080293639A1 (en) * | 2005-04-29 | 2008-11-27 | The Regents Of The University Of California | Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response |
MX2007013430A (es) * | 2005-04-29 | 2008-03-19 | Univ California | Peptidos y peptidos mimeticos para tratar patologias caracterizadas por una respuesta inflamatoria. |
GR1005428B (el) * | 2005-05-27 | 2007-02-01 | Χαραλαμπος Αλεξοπουλος | Συνθετικα λιποπεπτιδια με αντιαθηρογονο δραση, που εμποδιζουν την οξειδωση της λιποπρωτεϊνης χαμηλης πυκνοτητας (ldl) και αναστελλουν την απενεργοποιηση του ενζυμου της paf ακετυλοϋδρολασης (paf-ah) |
GB0513096D0 (en) | 2005-06-28 | 2005-08-03 | Strathclyde | Treatment of microbial infections |
WO2007055873A2 (en) * | 2005-11-04 | 2007-05-18 | Avanir Pharmaceuticals | Process for the manufacture of peptide facilitators of reverse cholesterol transport |
US8440695B2 (en) * | 2005-11-09 | 2013-05-14 | St Jude Children's Research Hospital | Use of chloroquine to treat metabolic syndrome |
CA2653840A1 (en) * | 2006-06-01 | 2007-12-06 | Institut De Cardiologie De Montreal | Use of a peptide/phospholipid complex acting as a reverse lipid transport agonist for treatment of valvular stenosis |
WO2007149355A2 (en) * | 2006-06-16 | 2007-12-27 | Lipid Sciences, Inc. | Novel peptides that promote lipid efflux |
US20080206142A1 (en) * | 2006-06-16 | 2008-08-28 | Lipid Sciences, Inc. | Novel Peptides That Promote Lipid Efflux |
US20080227686A1 (en) * | 2006-06-16 | 2008-09-18 | Lipid Sciences, Inc. | Novel Peptides that Promote Lipid Efflux |
CA2659655A1 (en) * | 2006-08-08 | 2008-02-21 | Alan M. Fogelman | Salicylanilides enhance oral delivery of therapeutic peptides |
WO2008039843A2 (en) * | 2006-09-26 | 2008-04-03 | Lipid Sciences, Inc. | Novel peptides that promote lipid efflux |
CA2672131C (en) * | 2006-12-13 | 2016-06-07 | The Regents Of The University Of California | Potent and selective mediators of cholesterol efflux |
US20080268038A1 (en) * | 2007-04-26 | 2008-10-30 | Wolfe Robert R | Compositions and Approaches for Increasing Diet Induced Thermogenesis, Inducing Weight Loss and Maintaining Muscle Mass and Strength |
RU2010104042A (ru) * | 2007-07-09 | 2011-08-20 | Новартис АГ (CH) | Сохранение вторичной структуры пептида |
CA2697957A1 (en) | 2007-08-28 | 2009-03-12 | Uab Research Foundation | Synthetic apolipoprotein e mimicking polypeptides and methods of use |
DK2682400T5 (da) | 2007-08-28 | 2017-11-27 | Uab Research Foundation | Syntetiske apolipoprotein E-efterlignende polypeptider og fremgangsmåder til anvendelse |
KR20100080519A (ko) * | 2007-08-30 | 2010-07-08 | 큐어디엠 인코포레이티드 | 프로섬 펩타이드 및 이의 유사체의 조성물 및 이의 이용 방법 |
US20110300130A1 (en) * | 2007-12-11 | 2011-12-08 | Becker David L | Impaired wound healing compositions and treatments |
US20110020242A1 (en) * | 2007-12-12 | 2011-01-27 | Gang Zheng | High-density lipoprotein-like peptide-phospholipid scaffold ("hpps") nanoparticles |
WO2010014830A2 (en) * | 2008-07-30 | 2010-02-04 | Cosmix Therapeutics Llc | Peptide therapeutics that bind vegf and methods of use thereof |
ITTO20080894A1 (it) * | 2008-12-02 | 2010-06-03 | Bioindustry Park Del Canavese S P A | Uso dell'aptoglobina, peptidi leganti l'aptoglobina, polimeri contenenti gli stessi e loro uso |
SI2396017T1 (sl) | 2009-02-16 | 2015-12-31 | Cerenis Therapeutics Holding Sa | Mimika apolipoproteina A-1 |
US20120270771A1 (en) * | 2009-09-30 | 2012-10-25 | Snu R&Db Foundation | Apolipoprotein a-1 mimic peptides, and therapeutic agent for treating hyperlipidemia and diseases related to hyperlipidemia comprising same |
WO2011044545A2 (en) | 2009-10-09 | 2011-04-14 | Sigalov Alexander B | Methods and compositions for targeted imaging |
US10894098B2 (en) | 2012-04-09 | 2021-01-19 | Signablok, Inc. | Methods and compositions for targeted imaging |
NO2385374T3 (de) | 2010-05-05 | 2014-06-07 | ||
EP3293522A3 (de) * | 2010-06-20 | 2018-05-02 | Zora Biosciences OY | Lipidomik-biomarker zur identifizierung von patienten mit hohem risiko einer koronararterienerkrankung |
WO2012108990A2 (en) * | 2011-02-07 | 2012-08-16 | Indiana University Research And Technology Corporation | Peptide-phospholipid conjugates |
LT2673296T (lt) | 2011-02-07 | 2019-02-25 | Cerenis Therapeutics Holding Sa | Lipoproteino kompleksai ir jų gamyba ir jų panaudojimai |
US9539300B2 (en) | 2012-03-31 | 2017-01-10 | The Regents Of The University Of California | Modulating disease through genetic engineering of plants |
RU2662973C2 (ru) * | 2012-11-06 | 2018-07-31 | Лез Опито Юниверситер Де Женев | Пептидомиметики |
WO2014152776A1 (en) | 2013-03-14 | 2014-09-25 | Uab Research Foundation | Apolipoprotein mimetics and uses thereof |
JP6549554B2 (ja) | 2013-03-15 | 2019-07-24 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | コレステロール流出を刺激する、減少した毒性を有するペプチド |
WO2014174517A1 (en) | 2013-04-25 | 2014-10-30 | Carmel-Haifa University Economic Corp. | Synthetic anti-inflammatory peptides and use thereof |
EP2853259A1 (de) | 2013-09-30 | 2015-04-01 | Université Pierre et Marie Curie (Paris 6) | Rekonstituierte hochdichte Lipoproteinzusammensetzung und Verwendungen davon |
WO2015173633A2 (en) | 2014-05-02 | 2015-11-19 | Cerenis Therapeutics Holding Sa | Hdl therapy markers |
WO2016018665A1 (en) | 2014-07-31 | 2016-02-04 | Uab Research Foundation | Apoe mimetic peptides and higher potency to clear plasma cholesterol |
US10532105B2 (en) | 2015-07-10 | 2020-01-14 | Peptinovo Biopharma, LLC. | Formulations for improving the efficacy of hydrophobic drugs |
CN105061579B (zh) * | 2015-08-18 | 2018-08-28 | 北京大学人民医院 | 脂多糖结合蛋白在制备类风湿关节炎相关药物中的应用 |
WO2018002673A1 (en) | 2016-07-01 | 2018-01-04 | N4 Pharma Uk Limited | Novel formulations of angiotensin ii receptor antagonists |
CA3032229A1 (en) | 2016-07-27 | 2018-02-01 | Hartis-Pharma Sa | Therapeutic combinations to treat red blood cell disorders |
WO2018063796A1 (en) | 2016-09-28 | 2018-04-05 | The Regents Of The University Of California | Ezetimibe-associated apoa-1 mimetic peptides showing enhanced synergism |
US10426817B2 (en) | 2017-01-24 | 2019-10-01 | Macregen, Inc. | Treatment of age-related macular degeneration and other eye diseases with apolipoprotein mimetics |
IL297336A (en) | 2020-04-16 | 2022-12-01 | Abionyx Pharma Sa | Methods for the treatment of serious conditions by lipid binding complexes of basic proteins |
AU2021354095A1 (en) | 2020-10-01 | 2023-06-08 | Abionyx Pharma Sa | Compositions comprising lipid binding protein-based complexes for use for treating eye diseases |
RU2760498C1 (ru) * | 2021-02-09 | 2021-11-25 | Вахтанг Владимирович Гобеджишвили | Способ прогнозирования развития избыточного рубцеобразования у больных после проктологической операции |
JP2024514154A (ja) | 2021-04-15 | 2024-03-28 | アビオニクス ファーマ エスエー | 臓器保存溶液における脂質結合タンパク質ベースの複合体の使用 |
WO2023168350A2 (en) * | 2022-03-03 | 2023-09-07 | University Of Maryland, Baltimore | Synthetic amphipathic helical peptides and treatment methods using synthetic amphipathic helical peptides |
WO2023194798A1 (en) | 2022-04-06 | 2023-10-12 | Abionyx Pharma Sa | Methods for treating leukocytosis, endothelial dysfunction and carditis using lipid binding protein-based complexes |
WO2023194797A1 (en) | 2022-04-06 | 2023-10-12 | Abionyx Pharma Sa | Methods for treating eye diseases using lipid binding protein-based complexes |
WO2023237927A2 (en) | 2022-06-10 | 2023-12-14 | Abionyx Pharma Sa | Methods for treating hyperinflammatory conditions using lipid binding protein -based complexes |
WO2023237935A2 (en) | 2022-06-10 | 2023-12-14 | Abionyx Pharma Sa | Methods for treating acute conditions using lipid binding protein-based complexes |
Family Cites Families (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3767040A (en) | 1971-03-01 | 1973-10-23 | Minnesota Mining & Mfg | Pressure-sensitive polyurethane adhesives |
US4155913A (en) | 1973-02-08 | 1979-05-22 | Hoffmann-La Roche Inc. | Thienotriazolodiazepine derivatives |
NO812612L (no) | 1980-08-06 | 1982-02-08 | Ferring Pharma Ltd | Enzym-inhibitorer. |
US4643988A (en) | 1984-05-15 | 1987-02-17 | Research Corporation | Amphipathic peptides |
US5182261A (en) * | 1989-07-13 | 1993-01-26 | The Rockefeller University | Modified transforming growth factor alpha oligopeptides and pharmaceutical compositions thereof |
AU662885B2 (en) | 1990-06-07 | 1995-09-21 | Scripps Research Institute, The | APO AI polypeptides, antibodies, and immunoassays |
GB9022788D0 (en) | 1990-10-19 | 1990-12-05 | Cortecs Ltd | Pharmaceutical formulations |
US5646119A (en) * | 1991-11-01 | 1997-07-08 | Periodontix, Inc. | D-amino acid histatin-based peptides as anti-fungal and anti-bacterial agents |
SE9103701D0 (sv) * | 1991-12-13 | 1991-12-13 | Kabi Pharmacia Ab | Apolipoprotein |
JPH07507554A (ja) | 1992-06-12 | 1995-08-24 | エヌ・ブイ・イノゲネテイクス・エス・エイ | 新規ペプチドおよびタンパク質,それらの調製方法,ならびにコレステロール受容体としてのそれらの使用 |
US5344822A (en) | 1992-08-12 | 1994-09-06 | The Rogosin Institute | Methods useful in endotoxin prophylaxis and therapy |
WO1994004563A1 (en) | 1992-08-14 | 1994-03-03 | Shino-Test Corporation | PEPTIDES CONTAINING RESPECTIVE AMINO ACID SEQUENCES SELECTED FROM AMONG THOSE OF LIPOPROTEIN(a) AND APOLIPOPROTEIN(a), ANTIBODIES RESPECTIVELY RECOGNIZING THESE AMINO ACID SEQUENCES, AND METHOD OF ASSAYING WITH THESE ANTIBODIES |
US5721138A (en) | 1992-12-15 | 1998-02-24 | Sandford University | Apolipoprotein(A) promoter and regulatory sequence constructs and methods of use |
AU698962B2 (en) * | 1993-09-14 | 1998-11-12 | Epimmune, Inc. | Alteration of immune response using pan DR-binding peptides |
US6169073B1 (en) * | 1995-02-16 | 2001-01-02 | Bayer Corporation | Peptides and peptidomimetics with structural similarity to human p53 that activate p53 function |
KR19990044460A (ko) | 1995-09-09 | 1999-06-25 | 프리돌린 클라우스너, 롤란드 비. 보레르 | 아포리포단백질 에이-아이의 양을 증대시키는 티에노트리아졸로디아제핀의 용도 |
US5912014A (en) | 1996-03-15 | 1999-06-15 | Unigene Laboratories, Inc. | Oral salmon calcitonin pharmaceutical products |
WO1997036927A1 (en) | 1996-03-29 | 1997-10-09 | Dario Boffelli | Amphipathic molecules as cholesterol and other lipid uptake inhibitors |
US6200955B1 (en) * | 1996-06-11 | 2001-03-13 | Commonwealth Biotechnologies, Inc. | Heparin binding peptides |
WO1998009602A2 (en) * | 1996-09-05 | 1998-03-12 | The Uab Research Foundation | Anti-atherosclerotic peptides and a transgenic mouse model of atherosclerosis |
US6696545B1 (en) * | 1997-04-11 | 2004-02-24 | Sangstat Medical Corporation | Cytomodulating lipophilic peptides for modulating immune system activity and inhibiting inflammation |
IN185761B (de) | 1997-05-13 | 2001-04-28 | Council Scient Ind Res | |
US6004925A (en) | 1997-09-29 | 1999-12-21 | J. L. Dasseux | Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders |
US6037323A (en) * | 1997-09-29 | 2000-03-14 | Jean-Louis Dasseux | Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders |
US6046166A (en) | 1997-09-29 | 2000-04-04 | Jean-Louis Dasseux | Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders |
US6518412B1 (en) | 1997-09-29 | 2003-02-11 | Jean-Louis Dasseux | Gene therapy approaches to supply apolipoprotein A-I agonists and their use to treat dyslipidemic disorders |
US6287590B1 (en) | 1997-10-02 | 2001-09-11 | Esperion Therapeutics, Inc. | Peptide/lipid complex formation by co-lyophilization |
AU3356899A (en) | 1998-03-17 | 1999-10-11 | Uab Research Foundation, The | Synthetic peptides that enhance ldl uptake |
KR20010099605A (ko) * | 1998-07-30 | 2001-11-09 | 존 프랫 | Hiv 막융합 억제제 |
US6664230B1 (en) | 2000-08-24 | 2003-12-16 | The Regents Of The University Of California | Orally administered peptides to ameliorate atherosclerosis |
-
2000
- 2000-08-24 US US09/645,454 patent/US6664230B1/en not_active Expired - Lifetime
-
2001
- 2001-06-29 US US09/896,841 patent/US6933279B2/en not_active Expired - Lifetime
- 2001-08-23 DE DE60141842T patent/DE60141842D1/de not_active Expired - Lifetime
- 2001-08-23 DE DE60144543T patent/DE60144543D1/de not_active Expired - Lifetime
- 2001-08-23 CA CA2639651A patent/CA2639651C/en not_active Expired - Lifetime
- 2001-08-23 AU AU8673201A patent/AU8673201A/xx active Pending
- 2001-08-23 CN CN200510103876A patent/CN100579984C/zh not_active Expired - Lifetime
- 2001-08-23 CN CNB018172806A patent/CN1224419C/zh not_active Expired - Lifetime
- 2001-08-23 ES ES01966198T patent/ES2342258T3/es not_active Expired - Lifetime
- 2001-08-23 EA EA200501744A patent/EA009528B1/ru not_active IP Right Cessation
- 2001-08-23 EP EP07007775A patent/EP1864675B1/de not_active Expired - Lifetime
- 2001-08-23 CN CN200610100669.3A patent/CN1931359B/zh not_active Expired - Lifetime
- 2001-08-23 CN CN2006101006689A patent/CN1943781B/zh not_active Expired - Lifetime
- 2001-08-23 AT AT01966198T patent/ATE464060T1/de active
- 2001-08-23 CA CA2718348A patent/CA2718348C/en not_active Expired - Lifetime
- 2001-08-23 CN CNA2006101006674A patent/CN1931358A/zh active Pending
- 2001-08-23 AT AT07007775T patent/ATE506958T1/de not_active IP Right Cessation
- 2001-08-23 AU AU2001286732A patent/AU2001286732B2/en not_active Expired
- 2001-08-23 CA CA002420222A patent/CA2420222C/en not_active Expired - Lifetime
- 2001-08-23 DK DK01966198.2T patent/DK1318828T3/da active
- 2001-08-23 EP EP10002402.5A patent/EP2198877B1/de not_active Expired - Lifetime
- 2001-08-23 ES ES10002402.5T patent/ES2438779T3/es not_active Expired - Lifetime
- 2001-08-23 EA EA200300289A patent/EA006488B1/ru not_active IP Right Cessation
- 2001-08-23 JP JP2002520844A patent/JP3822167B2/ja not_active Expired - Lifetime
- 2001-08-23 EP EP01966198A patent/EP1318828B1/de not_active Expired - Lifetime
- 2001-08-23 IL IL15454501A patent/IL154545A0/xx active IP Right Grant
- 2001-08-23 CN CNA2006101006706A patent/CN1911439A/zh active Pending
- 2001-08-23 WO PCT/US2001/026497 patent/WO2002015923A1/en active Application Filing
- 2001-08-23 PT PT01966198T patent/PT1318828E/pt unknown
-
2003
- 2003-02-19 IL IL154545A patent/IL154545A/en unknown
- 2003-10-29 HK HK08104243.9A patent/HK1110011A1/xx not_active IP Right Cessation
- 2003-10-29 HK HK03107790.4A patent/HK1055400A1/xx not_active IP Right Cessation
-
2005
- 2005-10-19 JP JP2005304531A patent/JP4205713B2/ja not_active Expired - Lifetime
-
2006
- 2006-01-06 AU AU2006200035A patent/AU2006200035B2/en not_active Expired
- 2006-08-14 JP JP2006220831A patent/JP4364222B2/ja not_active Expired - Lifetime
-
2007
- 2007-04-27 JP JP2007118451A patent/JP2007277250A/ja not_active Withdrawn
- 2007-09-26 JP JP2007250264A patent/JP2008150358A/ja active Pending
-
2009
- 2009-07-03 AU AU2009202705A patent/AU2009202705C1/en not_active Expired
-
2010
- 2010-05-31 IL IL206114A patent/IL206114A/en active IP Right Grant
- 2010-07-14 CY CY20101100656T patent/CY1110204T1/el unknown
- 2010-09-10 JP JP2010203789A patent/JP5241790B2/ja not_active Expired - Lifetime
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE464060T1 (de) | Peroral-verabreichte peptide zur besserung von atherosklerose | |
ATE516811T1 (de) | Peptide vom g-typ zur linderung von atherosklerose | |
ATE460429T1 (de) | Polypeptide enthaltend extrazellulären domäne von il-20ra und/oderr il-20rb | |
DE50112802D1 (de) | Peptide, deren herstellung und verwendung zur bindung von immunglobulinen | |
BR0205983A (pt) | fármacos peptìdicos antiangiogênicos | |
NO20073914L (no) | Biologisk aktive peptider | |
DK1908772T3 (da) | Polypeptider og polynucleinsyrer af phorphorymonas gingivalis | |
BR9714376A (pt) | Antagonistas de somatostatina | |
DK1219299T4 (da) | Allergivacciner og fremstilling deraf | |
WO2002031127A3 (en) | Cloning and recombinant expression of mammalian group xii secreted phospholipase a¿2? | |
DE60021707D1 (de) | Beta-primeverosidase gen | |
BR0107799A (pt) | Proteìna de interação de wt1 wtip |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
UEP | Publication of translation of european patent specification |
Ref document number: 1318828 Country of ref document: EP |